ANI Pharmaceuticals, Inc. (ANIP)
Automate Your Wheel Strategy on ANIP
With Tiblio's Option Bot, you can configure your own wheel strategy including ANIP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ANIP
- Rev/Share 34.3789
- Book/Share 22.6179
- PB 2.9301
- Debt/Equity 0.7585
- CurrentRatio 2.6573
- ROIC 0.0047
- MktCap 1354492816.0
- FreeCF/Share 3.4869
- PFCF 19.8121
- PE -58.277
- Debt/Assets 0.2457
- DivYield 0
- ROE -0.0486
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ANIP | Jefferies | -- | Buy | -- | $80 | March 14, 2025 |
| Initiation | ANIP | JP Morgan | -- | Overweight | -- | $85 | March 12, 2025 |
| Initiation | ANIP | Leerink Partners | -- | Outperform | -- | $80 | Dec. 11, 2024 |
| Initiation | ANIP | Piper Sandler | -- | Overweight | -- | $68 | Oct. 11, 2024 |
News
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purified Cortrophin Gel for the treatment of acute gout flares PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the initiation of a Phase 4 clinical trial at Massachusetts General Hospital to compare the safety and efficacy of two dose levels (40 USP units and 80 USP …
Read More
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants Gary Nachman - Raymond James Faisal Khurshid - Leerink Partners Vamil Divan - Guggenheim Securities David Amsellem - Piper Sandler Ekaterina Knyazkova - J.P. Morgan Les Sulewski - Truist Securities Operator Please stand by.
Read More
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.
Read More
Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key Metrics
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.70 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $1.21 per share a year ago.
Read More
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
BAUDETTE, Minn., May 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended March 31, 2025.
Read More
ANI Pharmaceuticals: A Short-Term Buying Opportunity
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
ANIP is expected to raise 2025 guidance due to FDA approval and launch of TEZRULY and INZIRQO, addressing unmet needs for dysphagic patients. Both drugs are patent protected until 2042 and offer new formulations of established drugs, minimizing launch expenses and maximizing market potential. INZIRQO and TEZRULY could generate significant revenue, with potential annual revenues of $1 billion and $350 million respectively, driving ANIP's PPS higher.
Read More
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
ANIP's first-quarter 2025 revenues are likely to have been driven by increased sales of its lead product, Cortrophin Gel, and other rare disease products.
Read More
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
3 Reasons Growth Investors Will Love ANI (ANIP)
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Read More
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.
Read More
Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Stride, 908 Devices, & Contango are well-poised to gain.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Read More
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how ANI Pharmaceuticals (ANIP) and Galectin Therapeutics Inc. (GALT) have performed compared to their sector so far this year.
Read More
Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGO
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Expand Energy, Avista & Contango are well-poised to gain.
Read More
Is the Options Market Predicting a Spike in ANI Pharmaceuticals (ANIP) Stock?
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to ANI Pharmaceuticals (ANIP) stock based on the movements in the options market lately.
Read More
5 Relative Price Strength Stocks to Navigate Today's Market
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
IHS, ANIP, MD, FMS and TREE are five stocks with explosive relative price strength.
Read More
5 High Earnings Yield Value Picks to Counter Market Uncertainty
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Unlock your portfolio value with high earnings yield stocks like ANI Pharma, Insteel, Pitney Bowes, IHS Holding and HighPeak Energy.
Read More
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross?
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI Pharmaceuticals, Inc. (ANIP) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ANIP's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Read More
Wall Street Analysts Think ANI (ANIP) Could Surge 26.83%: Read This Before Placing a Bet
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for ANI (ANIP) points to a 26.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Relative Price Strength: A Smart Strategy Amid Market Turmoil
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Positive
OOMA, ANIP, MATX, VIRT and EVER are five stocks with explosive relative price strength.
Read More
Wall Street Analysts Believe ANI (ANIP) Could Rally 32.4%: Here's is How to Trade
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for ANI (ANIP) points to a 32.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Read More
ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
About ANI Pharmaceuticals, Inc. (ANIP)
- IPO Date 2000-05-05
- Website https://www.anipharmaceuticals.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Nikhil Lalwani
- Employees 897